CTKB

Cytek BiosciencesC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

Faster instrument placements, higher consumables attach rates, and margin expansion drive durable revenue growth and multiple expansion, supporting a re‑rating toward the upper end of published analyst targets.

Posture

Mixed

Lead driver

Sentiment

What changed

Sentiment remains the lead driver in the composite, 7D delta -4.6.

What can break

Negative analyst revisions after quarterly results could trigger near-term share weakness.

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $5.73 · Bull $9.00 · Bear $3.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-01-29 • Model: RankAlpha Sentiment AI

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net —

Target $5.69

Why

Momentum49 · Δ7d -1.5

Value41 · Δ7d -0.1

Sentiment72 · Δ7d -4.6

So what

Balanced signals. Wait for confirmation before sizing up.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Sentiment · See AI snapshot

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

-1.5

Δ21d

+1.8

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-4.6

Δ21d

-5.8

Why this grade

Composite grade C. Momentum 49.1 / Value 41.1 / Sentiment 71.8

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$596.64M

Beta

1.30

Shares Out

129.14M

P/E (TTM) · Derived

-8.9

P/S (TTM)

3.38

P/FCF (TTM)

53.79

Rev YoY

+6.5%

EPS YoY

+65.1%

Gross Margin

+51.7%

Op Margin

-16.2%

Net Debt

-$228.51M

Current Ratio

4.69

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology